The combined antidiuretic effect of oxytocin and the i.v. The pharmacological induction itself and not a particular agent is linked to such risk. ���l��6��`BlW���������p MX��"��W/�`�(��_���5�����y\H�\�Z��-%������E@؏ <>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> x��[�n�8}��ck��E���Ǘ�;�83d�Ai�ma���x�W��[�H�Ŷ)k��`�j�X,�r��>8j�zY. infusion and never by i.v. When Syntocinon is given by continuous i.v. PPH remains one of the major causes of maternal mortality in the world. ���� ���4M�b��x�)��)|n���s݊��;.���~�p�ng8b�� ��Ԛ����"H_ 4.5 Interaction with other medicinal products and other forms of interaction6.6 Special precautions for disposal and other handling9. Due to the existing structural homology between oxytocin and latex, latex allergy/intolerance may be an important predisposing risk factor for anaphylaxis following oxytocin administration.Interaction resulting in a concomitant use not recommendedProstaglandins and its analogues facilitate contraction of the myometrium hence oxytocin can potentiate the uterine action of prostaglandins and analogues and vice versa (see section 4.3 Contraindications).Oxytocin should be considered as potentially arrhythmogenic, particularly in patients with other risk factors for Torsades de Pointes such as drugs which prolong the QT interval or in patients with history of long QT syndrome (see section 4.4 Special warnings and precautions for use).Inhalation anaesthetics (e.g.
Prevention of postpartum uterine haemorrhage: The usual dose is 5 IU by i.v. Syntocinon can induce labour, therefore caution should be exercised when driving or operating machines. Store at room temperature (15-25°C) Do not freeze. These rapid haemodynamic changes may result in myocardial ischaemia, particularly in patients with pre-existing cardiovascular disease. 1�Z9>�� Syntocinon should be administered as an intravenous (i.v.) No studies have been performed in renally impaired patients. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme (www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.The fatal dose of Syntocinon has not been established. Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. The trials evaluated the effect of both forms of administration after both vaginal delivery and caesarean section, and compared the results to the use of oxytocin, fixed dose oxytocin-ergometrine, and placebo. b%�-��V˝I \�g�s�iNR��_�yߺ&QĹ��7��ȵ?Og��5T�Al�|��=_d�c\��~1[���q#FR]�n&�����? %���� Treatment of postpartum uterine haemorrhage: 5 IU by i.v. Therefore, biotransformation of oxytocin in impaired hepatic function may not result in substantial changes in metabolic clearance of oxytocin.Pre-clinical data for oxytocin reveal no special hazard for humans based on conventional studies of single dose acute toxicity, genotoxicity, and mutagenicity.Sodium acetate tri-hydrate, acetic acid, chlorobutanol, ethanol and water for injections.Syntocinon should not be infused via the same apparatus as blood or plasma, because the peptide linkages are rapidly inactivated by oxytocin-inactivating enzymes. fluid administration may cause fluid overload leading to a haemodynamic form of acute pulmonary oedema without hyponatraemia. PPH can be further classified into primary PPH (within 24 hours of birth) and secondary (between 24 hours and six weeks postpartum). Any condition in which, for foetal or maternal reasons, spontaneous labour is inadvisable and/or vaginal delivery is contra-indicated: e.g. Plasma protein binding is negligible for oxytocin. It allows continued monitoring of the benefit/risk balance of the medicinal product. Induction or enhancement of labour: Oxytocin should not be started for 6 hours following administration of vaginal prostaglandins. �9(dOR�L� �mھ��W��]k�y���]; Liver and kidney plays a major role in metabolising and clearing oxytocin from the plasma. Lactation Oxytocin may be found in small quantities in mother's breast milk. The metabolic clearance rate amounts to 20 mL/kg/ min in the pregnant woman. Dexmedetomidine also has uterotonic effects, which was beneficial in controlling this PPH.
The oxytocin receptors are G-proteins coupled receptors.